

ScinoPharm Taiwan, Ltd.
Notice of 2024 Annual General Shareholders' Meeting
(Summary Translation)

The 2024 Annual General Shareholders' Meeting (the "Meeting") of ScinoPharm Taiwan, Ltd. (the "Company") will be convened at 10:00 a.m., Tuesday, May 28, 2024 at ScinoPharm Taiwan, Ltd. (1 Nan-Ke 8th Road, Southern Taiwan Science Park, Shan-Hua, Tainan, Taiwan).

Convene Format: Physical Shareholders' Meeting

1. The agenda for the Meeting is as follows:

I. Report Items

- (1) 2023 Business Report.
- (2) Audit Committee's Review Report on 2023 Financial Results.
- (3) 2023 Remuneration for Employees and Directors.

II. Ratification Items

- (1) Ratification of 2023 Business Report and Financial Statements.
- (2) Ratification of the Proposed Distribution of 2023 Earnings.

III. Election

- (1) The 11th Election of Board of Directors

IV. Other Proposals

- (1) Proposed release the Directors (including Independent Directors) and their representatives from non-competition restrictions

V. Extemporaneous motions

2. Proposal for distribution of 2023 profits has been resolved by the Board of Directors as follows:

Proposed cash dividend is \$237,221,766, which is equivalent to \$0.3 per share. Upon the approval of Annual General Shareholders' Meeting, it is proposed that the Board of Directors be authorized to resolve the distribution record date.

3. Pursuant to Article 165 of the Company Act, the Company hereby closes the share transfer registration from March 30 2024 to May 28, 2024.

4. If any shareholder solicits for a proxy, the Company will disclose the summarization of the solicitation prepared by the Company on the website of the Securities and Futures Institute (<http://free.sfi.org.tw>) on April 26, 2024. If any investor wishes to make inquiries, please log into the "free inquiry system for published information of proxy" on the website, and click the right side "entrance to published information of proxy" and input the key words for the inquiry.

5. The shareholder's voting power of this annual shareholders' meeting may be exercised by way of electronic transmission, and the exercising period will be from April 27, 2024 through May 25, 2024. Please log in the "Stockvote" established by Taiwan Depository & Clearing Corporation at <https://stockservices.tdcc.com.tw>.
6. The institution for tallying and verifying proxy forms of 2024 general shareholders' meeting is Stock Registration Department, President Securities Corporation.
7. If there exist any matters that shall be itemized in the causes and the essential contents thereof shall be explained pursuant to Article 172 of the Company Law, the essential contents can be found at the Market Observation Post System (<http://mops.twse.com.tw>). Please log into said website, and click "electronic books", key in the Year "2024," select the code of the Company "1789," and read references related to the shareholders' meeting.

Board of Directors
ScinoPharm Taiwan, Ltd.